Elacridar (hydrochloride) (Standard)

Elacridar (hydrochloride) (Standard) is the analytical standard of Elacridar (hydrochloride) . This product is intended for research and analytical applications. Elacridar hydrochloride (GF120918A) is an orally active P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) inhibitor. Elacridar hydrochloride can be used to examine the influence of efflux transporters on agent distribution to brain and it can be used for the research of cancer[1][2].

Product Specifications

CAS Number

[143851-98-3]

UNSPSC

12352100

Target

BCRP; P-glycoprotein; Reference Standards

Related Pathways

Membrane Transporter/Ion Channel; Others

Field of Research

Cancer

Smiles

O=C1C2=CC=CC(C(NC(C=C3)=CC=C3CCN4CC(C=C(C(OC)=C5)OC)=C5CC4)=O)=C2NC6=C1C=CC=C6OC.[H]Cl

Molecular Formula

C34H34ClN3O5

Molecular Weight

600.10

References & Citations

[1]Sane R, et al. Brain distribution and bioavailability of elacridar after different routes of administration in the mouse. Drug Metab Dispos. 2012 Aug;40 (8) :1612-9.|[2]Sato H, et al. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells. Eur J Pharmacol. 2015 Jan 5;746:258-66.